ÀÏ»¢»ú¹¥ÂÔ

Personal Summary

Erica Woodahl, Ph.D. is a Professor in the Department of Biomedical and Pharmaceutical Sciences and Director of the Skaggs Institute for Health Innovation at the ÀÏ»¢»ú¹¥ÂÔ. Erica Woodahl received a B.S. in Biochemistry at the University of Notre Dame and a Ph.D. from the Department of Pharmaceutics at the University of Washington. She completed a postdoctoral fellowship in clinical pharmacokinetics at the Fred Hutchinson Cancer Research Center in Seattle. She joined the faculty at the ÀÏ»¢»ú¹¥ÂÔ in 2007 as an Assistant Professor, was promoted to Associate Professor in 2012, and promoted to Professor in 2020. Dr. Woodahl’s research focuses on precision medicine and pharmacogenomics to identify sources of interindividual variability in disease treatment and prevention. Translation of pharmacogenomics into clinical practice requires genetic research with diverse patient populations to accurately predict drug response and toxicity for all people regardless of geographic location, ethnicity, or age. We use community-based participatory research to address complex and important challenges to conducting precision medicine research and aid in the translation of precision medicine research into the clinic.

Education

B.S. Biochemistry; University of Notre Dame (1998)

Ph.D. Pharmaceutics; University of Washington (2004)

Postdoctoral Fellow; Fred Hutchinson Cancer Research Center

Research Interests

Please visit the  to learn more!

The research focus of the Woodahl laboratory is on precision medicine and pharmacogenomics to identify sources of interindividual variability in disease treatment and prevention (e.g. genes, environment, and lifestyle). We are interested in genetic and environmental factors that alter the pharmacokinetics, or ADME (absorption, distribution, metabolism, and elimination), and pharmacodynamics of many therapeutic compounds. Translation of pharmacogenomics into clinical practice requires genetic research with diverse patient populations to accurately predict drug response and toxicity for all people. Towards this end, we focus on precision medicine and pharmacogenomics with rural and underserved populations.

American Indian and Alaska Native populations in the United States have largely been left out of precision medicine and pharmacogenomics research. Our research is part of the , whose goals are to engage indigenous populations in precision medicine research (1U01GM092676 and P01GM116691). In Montana, we have established a community-academic partnership with the Confederated Salish and Kootenai Tribes living on the Flathead Reservation. This work includes the characterization of genetic variation and environmental factors that predict drug response and toxicity. Precision medicine research has broad utility across many therapeutic areas, with our primary focus on medications for the treatment of cardiovascular diseases and cancer. 

Our community-academic partnership is grounded in community-based participatory research to aid in the translation of precision medicine research into the clinic. We use community-engaged research to address complex and important challenges to conducting precision medicine research with American Indian and Alaska Native communities (R01HG009500) including alignment of research with tribal health priorities, developing community-responsive approaches to the return of research results to tribal participants and their communities, and addressing issues of data stewardship that support the full participation of tribal communities in research.

The Woodahl laboratory is also focused on understanding the mechanisms by which pharmacogenomics alter the function of drug-metabolizing enzymes (e.g. cytochrome P450 drug-metabolizing enzymes), drug transporters (e.g. ATP-binding cassette transporters), and regulatory proteins (e.g. vitamin D homeostasis) that contribute to drug disposition. We are using a combination of computational, membrane-based, cell-based, and in vivo models to study the functional consequence of genetic variation in drug-metabolizing enzymes and drug transporters.

Field of Study

Precision Medicine, Pharmacogenomics/Pharmacogenetics, Health Humanities, Health Equity, Rural and Tribal Populations

Publications

Complete List of Published Work in .

Leitch TM, Killam SR, Brown KE, Katseanes KC, George KM, Schwanke, C, Loveland J, Elias AF, Haney K, Krebsbach K, Muzquiz LI, Trinidad SB, Woodahl EL. Ensuring Equity: Pharmacogenetic Implementation in Rural and Tribal Communities. Front Pharmacol, in press.

Burke W, Beans JA, Benally M, Cho MK, Garrison NA, Hiratsuka V, Hopkins S, Spicer PG, Tsosie KS, Woodahl EL, Yracheta JM, Thummel K. Values and practices to strengthen genetic research partnerships with Indigenous communities. Prog Community Health Partnersh, in press.

Beans JA, Trinidad SB, Blacksher E, Hiratsuka VY, Spicer P, Woodahl EL, Boyer BB, Lewis CM, Gaffney PM, Garrison NA, Burke W. . Public Health Genomics, in press.

Blacksher, E, Trinidad SB, Woodbury RB, Hopkins SE, Woodahl EL, Boyer BB, Burke W, Hiratsuka, V. . J Empire Res Hum Res Ethics, in press.

Brown KE, Staples JW, Woodahl EL. . Pharmacogenomics, 23:255-262, 2022.

Trinidad SB, Blacksher E, Woodbury RB, Hopkins SE, Burke W, Woodahl EL, Boyer BB, Hiratsuka, VY. . Genet Med, 24:622-630, 2022.

Sangkuhl K, Claudio-Campos K, Cavallari LH, Agúndez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Botton MR, Woodahl EL, Stuart SA, Klein TE, Pratt VM,  Daly AK, Gaedigk A. . Clin Pharmacol Ther, 110:662-676, 2021.

Fohner AE, Dalton R, Skagen K, Jackson K, Claw KG, Hopkins SE, Robinson R, Khan BA, Prasad B, Schuetz EG, Nickerson DA, Thornton TA, Dillard DA, Boyer BB, Thummel KE, Woodahl EL. . Clin Transl Sci, 14:1292-1302, 2021.

Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. . Clin Pharmacol Ther, 109:352-366, 2021.

McInnes G, Dalton R, Sangkuhl K, Whirl-Carrillo M, Lee S, Tsao PS, Gaedigk A, Altman RB, Woodahl EL. . PLoS Comput Biol, 16:e1008399, 2020.

Staples JW, Stine JM, Mäki-Lohiluoma E, Steed E, George KM, Thompson CM, Woodahl EL. . Food Chem Toxicol, 146:111785, 2020.

Dalton R, Lee S, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. . Clin Transl Sci, 13:147-156, 2020.

Fohner AE, Volk KG, Woodahl EL. . Clin Pharmacol Ther 106:488-490, 2019.

Lee SB, Wheeler MM, Patterson K, McGee S, Dalton R, Woodahl EL, Gaedigk A, Thummel KE, Nickerson DA. . Genet Med 21:361-372, 2019.

Khan BA, Robinson R, Fohner AE, Muzquiz LI, Schilling BD, Beans JA, Olnes MJ, Trawicki L, Frydenlund H, Laukes C, Beatty P, Phillips B, Nickerson D, Howlett K, Dillard DA, Thornton TA, Thummel KE, Woodahl EL. . Clin Transl Sci 11:312-321, 2018.

Henderson LM, Claw KG, Woodahl EL, Robinson RF, Boyer BB, Burke W, Thummel KE. . J Pers Med 8, 9: 1-33, 2018.

Morales CT, Muzquiz LI, Howlett K, Azure B, Bodnar B, Finley V, Incashola T, Mathias C, Laukes C, Beatty P, Burke W, Pershouse MA, Putnam EA, Trinidad SB, James R, Woodahl EL. . Prog Community Health Partnersh 10:173-83, 2016.

Blunston MA, Yonovitz A, Woodahl EL, Smolensky MH. . Chronobiol Int 32:1223-32, 2015.

Lacher SE, Skagen K, Veit J, Dalton R, Woodahl EL. . J Pharmacol Exp Ther 355:99-107, 2015.

Trahey M Li MJ, Kwon H, Woodahl EL, McClary WD, Atkins WM. . Curr Protoc Protein Sci 81:29.13.1-29.13.16, 2015.

Dorfman EH, Trinidad SB, Morales CT, Howlett K, Burke W, Woodahl EL. . Pharmacogenomics 16:227-37, 2015.

Woodahl EL, Lesko LJ, Hopkins S, Robinson RF, Thummel KE, Burke W. . Pharmacogenomics 15:1235-41, 2014.

James R, Tsosie R, Sahota P, Parker M, Dillard D, Sylvester I, Lewis J, Klejka J, Muzquiz L, Olsen P, Whitener R, Burke W; Kiana Group*. . Genet Med 16:820-6, 2014. *Woodahl EL (member of Kiana Group)

Lacher SE, Gremaud JN, Skagen K, Steed E, Dalton R, Sugden KD, Cardozo-Pelaez F, Sherwin CMT, Woodahl EL. . J Pharmacol Exp Ther 348:336-45, 2014.

Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL. . Pharmacogenet Genomics 23:403-14, 2013.

McCune JS, Woodahl EL, Furlong T, Storer B, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV. . Cancer Chemother Pharmacol 69:263-72, 2012.

Boyer BB, Dillard D, Woodahl EL, Whitener R, Thummel KE, Burke W. . Clin Pharmacol Ther 89:343-5, 2011.

Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJY. . Cancer Chemother Pharmacol 64:183-188, 2009.

Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, McCune JS. . Cancer Chemother Pharmacol 63:959-964, 2009.

Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, O'Donnell PV, Phillips B, Risler L, Blough DK, McCune JS. . Cancer Chemother Pharmacol 63:391-401, 2009.

Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS. . Cancer Chemother Pharmacol 62:735-739, 2008.

Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS. . Pharmacogenomics J 8:248-255, 2008.

Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJY. . AIDS 14:1617-1625, 2005.

Woodahl EL and Ho RJY. . Curr Drug Metab 5:11-19, 2004.

Woodahl EL and Ho RJY. Augmentation of Cell-Mediated Immunity to Virus. In: Cellular Drug Delivery: Principle and Practice. Ed: D. Robert Lu and Svein Øie, Humana Press Inc., Totowa, NJ, 2004.

Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJY. . J Pharmacol Exp Ther 310:1199-1207, 2004.

Yang Z, Woodahl EL, Wang XY, Bui T, Shen DD, Ho RJY. . Biotechniques 33:196-203, 2002.

Affiliations

Graduate Programs

• Pharmaceutical Sciences and Drug Design
• Public Health
• Toxicology

Research Centers

• Skaggs Institute for Health Innovation
• Northwest-Alaska Pharmacogenomics Research Network
• Center for Biomolecular Structure and Dynamics
• Center for Translational Medicine

National

• Affiliate Professor, Department of Pharmaceutics, University of Washington
• Associate Editor, Clinical & Translational Sciences
• Past Chair, Translational & Precision Medicine Network, American Society for Clinical Pharmacology and Therapeutics
• CYP2C Expert Panel, Pharmacogene Variation (PharmVar) Consortium
• Co-Chair, Pharmacogenomics Global Research Network, Scientific Committee
• Member, ClinGen Pharmacogenomics Working Group
• Steering Committee, Special Populations Community, American Society for Clinical Pharmacology and Therapeutics
• Steering Committee, Rocky Mountain Discussion Group, American Association of Pharmaceutical Scientists